文献速递支持与姑息治疗

美国预后不良癌症患者临终前阿片类药物获取趋势

US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life.
PubMed 文献 · J Clin Oncol · 2021-07-22

该研究基于270,632例预后不良癌症的Medicare按服务收费死亡病例,分析2007至2017年临终前30天阿片处方及疼痛相关急诊就诊趋势。结果显示阿片处方比例和剂量显著下降,而疼痛相关急诊就诊比例上升,提示临终癌症疼痛管理可能恶化。

要点

  • 临终前获得至少一种阿片处方的比例从42.0%降至35.5%。
  • 长效阿片处方比例下降36.5%,日均剂量下降24.5%。
  • 疼痛相关急诊就诊比例上升50.8%,提示疼痛管理可能不足。

核心结论

  • 2007至2017年间,预后不良癌症患者临终前阿片类药物使用大幅下降,疼痛相关急诊就诊增加,提示临终癌症疼痛管理可能恶化。

研究设计与样本

  • 回顾性队列研究,纳入270,632例预后不良癌症的Medicare按服务收费死亡病例,使用Part D数据评估临终前30天阿片处方趋势。

主要发现

  • 临终前获得至少一种阿片处方的比例从42.0%(95%CI 41.4-42.7)降至35.5%(95%CI 34.9-36.0),相对下降15.5%。
  • 获得至少一种长效阿片处方的比例从18.1%(95%CI 17.6-18.6)降至11.5%(95%CI 11.1-11.9),相对下降36.5%。
  • 接受阿片者的日均剂量从85.6 MMED(95%CI 82.9-88.3)降至64.6 MMED(95%CI 62.7-66.6),下降24.5%。
  • 每例死亡者临终前阿片总量从1,075 MME(95%CI 1,042-1,109)降至666 MME(95%CI 646-686),下降38.0%。
  • 疼痛相关急诊就诊比例从13.2%(95%CI 12.7-13.6)升至19.9%(95%CI 19.4-20.4),相对增加50.8%。

临床怎么用

  • 肿瘤内科医生应关注临终癌症患者的疼痛评估与阿片可及性,避免因管制收紧导致疼痛控制不足。
  • 对临终前疼痛相关急诊就诊增加的趋势,需优化门诊和居家疼痛管理衔接。

局限性

  • 研究为观察性设计,无法确立因果关系。
  • 仅纳入Medicare按服务收费人群,结论外推需谨慎。
  • 使用行政索赔数据,可能存在编码偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Heightened regulations have decreased opioid prescribing across the United States, yet little is known about trends in opioid access among patients dying of cancer. METHODS: Among 270,632 Medicare fee-for-service decedents with poor prognosis cancers, we used part D data to examine trends from 2007 to 2017 in opioid prescription fills and opioid potency (morphine milligram equivalents per day [MMED]) near the end-of-life (EOL), defined as the 30 days before death or hospice enrollment. We used administrative claims to evaluate trends in pain-related emergency department (ED) visits near EOL. RESULTS: Between 2007 and 2017, the proportion of decedents with poor prognosis cancers receiving ≥ 1 opioid prescription near EOL declined 15.5% (relative percent difference [RPD]), from 42.0% (95% CI, 41.4 to 42.7) to 35.5% (95% CI, 34.9 to 36.0) and the proportion receiving ≥ 1 long-acting opioid prescription declined 36.5% (RPD), from 18.1% (95% CI, 17.6 to 18.6) to 11.5% (95% CI, 11.1 to 11.9). Among decedents receiving opioids near EOL, the mean daily dose fell 24.5%, from 85.6 MMED (95% CI, 82.9 to 88.3) to 64.6 (95% CI, 62.7 to 66.6) MMED. Overall, the total amount of opioids prescribed per decedent near EOL (averaged across those who did and did not receive an opioid) fell 38.0%, from 1,075 morphine milligram equivalents per decedent (95% CI, 1,042 to 1,109) to 666 morphine milligram equivalents per decedent (95% CI, 646 to 686). Simultaneously, the proportion of patients with pain-related ED visits increased 50.8% (RPD), from 13.2% (95% CI, 12.7 to 13.6) to 19.9% (95% CI, 19.4 to 20.4). Sensitivity analyses demonstrated similar declines in opioid utilization in the 60 and 90 days before death or hospice, and suggested that trends in opioid access were not confounded by secular trends in hospice utilization. CONCLUSION: Opioid use among patients dying of cancer has declined substantially from 2007 to 2017. Rising pain-related ED visits suggests that EOL cancer pain management may be worsening.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Enzinger AC, Ghosh K, Keating NL, et al. US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life. J Clin Oncol. 2021. PMID: 34292766. doi:10.1200/JCO.21.00476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。